Stay updated on CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Sign up to get notified when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.

Latest updates to the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page has undergone significant content changes, including the addition of 'T Cell Lymphoma' and 'CRSP-ONC-004', while key details about the study's design and inclusion/exclusion criteria have been removed.SummaryDifference16%
- Check15 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 8, 2025.SummaryDifference0.7%
- Check22 days agoNo Change Detected
- Check58 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check73 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check80 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.